Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Cash from Financing Activities (2016 - 2021)

Phio Pharmaceuticals' Cash from Financing Activities history spans 10 years, with the latest figure at -$1000.0 for Q4 2021.

  • For Q4 2021, Cash from Financing Activities changed N/A year-over-year to -$1000.0; the TTM value through Dec 2021 reached $21.7 million, up 34.66%, while the annual FY2025 figure was $23.6 million, 491.59% up from the prior year.
  • Cash from Financing Activities reached -$1000.0 in Q4 2021 per PHIO's latest filing, down from $21.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $21.7 million in Q1 2021 to a low of -$74000.0 in Q3 2017.
  • Average Cash from Financing Activities over 5 years is $3.8 million, with a median of $366000.0 recorded in 2017.
  • Peak YoY movement for Cash from Financing Activities: plummeted 99.61% in 2019, then skyrocketed 42188.89% in 2020.
  • A 5-year view of Cash from Financing Activities shows it stood at $366000.0 in 2017, then skyrocketed by 3558.47% to $13.4 million in 2018, then plummeted by 94.28% to $766000.0 in 2019, then crashed by 102.22% to -$17000.0 in 2020, then soared by 94.12% to -$1000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Cash from Financing Activities are -$1000.0 (Q4 2021), $21.7 million (Q1 2021), and -$17000.0 (Q3 2020).